M
Michael Thomas
Researcher at University Hospital Heidelberg
Publications - 335
Citations - 18268
Michael Thomas is an academic researcher from University Hospital Heidelberg. The author has contributed to research in topics: Lung cancer & non-small cell lung cancer (NSCLC). The author has an hindex of 46, co-authored 317 publications receiving 15321 citations. Previous affiliations of Michael Thomas include RMIT University & Heidelberg University.
Papers
More filters
Journal ArticleDOI
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw,Dong Wan Kim,Kazuhiko Nakagawa,Takashi Seto,Lucio Crinò,Myung-Ju Ahn,Tommaso De Pas,Benjamin Besse,Benjamin Solomon,Fiona H Blackhall,Yi-Long Wu,Michael Thomas,Kenneth J. O'Byrne,Denis Moro-Sibilot,D. Ross Camidge,Tony Mok,Vera Hirsh,Gregory J. Riely,Shrividya Iyer,V. Tassell,Anna Polli,Keith D. Wilner,Pasi A. Jänne +22 more
TL;DR: Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement and greater improvement in global quality of life with crizotinIB than with chemotherapy.
Journal ArticleDOI
Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw,Dong Wan Kim,Ranee Mehra,Daniel Shao-Weng Tan,Enriqueta Felip,Laura Q.M. Chow,D. Ross Camidge,Johan Vansteenkiste,Sunil Sharma,Tommaso De Pas,Gregory J. Riely,Benjamin Solomon,Juergen Wolf,Michael Thomas,Martin Schuler,Martin Schuler,Geoffrey Liu,Armando Santoro,Yvonne Y. Lau,Meredith Goldwasser,Anthony Boral,Jeffrey A. Engelman +21 more
TL;DR: Ceritinib was highly active in patients with advanced, ALK-rearranged NSCLC, including those who had had disease progression during crizotinib treatment, regardless of the presence of resistance mutations in ALK.
Journal ArticleDOI
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon,Tudor Ciuleanu,Oscar Arrieta,Kumar Prabhash,Konstantinos N. Syrigos,Tuncay Göksel,Keunchil Park,Vera Gorbunova,Ruben Dario Kowalyszyn,Joanna Pikiel,Grzegorz Czyzewicz,Sergey Orlov,Conrad R. Lewanski,Michael Thomas,Paolo Bidoli,Shaker R. Dakhil,Steven J.M. Gans,Joo Hang Kim,Alexandru Grigorescu,Nina Karaseva,Martin Reck,Federico Cappuzzo,Ekaterine Alexandris,Andreas Sashegyi,Sergey Yurasov,Maurice Pérol +25 more
TL;DR: Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC after platinum-based therapy and is registered with ClinicalTrials.gov.
Journal ArticleDOI
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).
Ajay K. Kakkar,Mark Levine,Zbigniew Kadziola,Nicholas R. Lemoine,Vanessa Low,Heman K. Patel,Gordon J. S. Rustin,Michael Thomas,Mary Quigley,Robin C.N. Williamson +9 more
TL;DR: Dalteparin administration did not significantly improve 1-year survival rates in patients with advanced malignancy, however, the observed improved survival in a subgroup of patients with a better prognosis suggests a potential modifying effect of dALTeparin on tumor biology.
Journal ArticleDOI
The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival
Arne Warth,Thomas Muley,Michael Meister,Albrecht Stenzinger,Michael Thomas,Peter Schirmacher,Philipp A. Schnabel,Jan Budczies,Hans Hoffmann,Wilko Weichert +9 more
TL;DR: Architectural grading of pulmonary ADCs according to the novel IASLC/ATS/ERS scheme is a rapid, straightforward, and efficient discriminator for patient prognosis and may support patient stratification for adjuvant chemoradiotherapy.